Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway.

Aging
Junfeng YeJinhai Yu

Abstract

The population of CD133 positive cancer cells has been reported to be responsible for drug resistance of hepatocellular carcinoma (HCC). However, the potential molecular mechanism by which CD133+ HCC cells develop drug resistance is still unclear. In this study, we found that CD133+ HepG2 and Huh7 cells were resistant to cisplatin treatment, compared to the CD133- HepG2 and Huh7 cells. However, treatment with osthole, a natural coumarin isolated from umbelliferae plant monomers, was found to resensitize CD133+ HepG2 and Huh7 cells to cisplatin treatment. In the mechanism research, we found that treatment with osthole increased the expression of PTEN. As a result, osthole inhibited the phosphorylation of AKT and Bad to decrease the amount of free Bcl-2 in CD133+ HepG2 and Huh7 cells. Finally, cisplatin-induced mitochondrial apoptosis was expanded. In conclusion, combination treatment with osthole can resensitize CD133+ HCC cells to cisplatin treatment via the PTEN/AKT pathway.

References

Dec 2, 1999·Genes & Development·S R DattaM E Greenberg
Nov 10, 2001·Trends in Biochemical Sciences·D P Brazil, B A Hemmings
Feb 8, 2005·The International Journal of Biochemistry & Cell Biology·Sergey V ShmelkovShahin Rafii
Aug 13, 2005·World Journal of Gastroenterology : WJG·Ping ZhengLun-Gen Lu
Mar 28, 2006·Cell·Michael F Clarke, Margaret Fuller
Feb 23, 2007·Planta medica·Qiaoyan ZhangNorbert De Kimpe
Sep 5, 2008·Annual Review of Pathology·Nader Chalhoub, Suzanne J Baker
Feb 25, 2009·European Journal of Pharmacology·Jarogniew J LuszczkiStanislaw J Czuczwar
Sep 10, 2009·Cell·Mark ShackletonSean J Morrison
Apr 17, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Yong-Sheng WangCai-Cun Zhou
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jul 30, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jianjian HuChenwei Pan
Dec 4, 2015·Drug Discoveries & Therapeutics·Shuzhan LiXiubao Ren
Apr 11, 2017·International Journal of Oncology·Depeng ShangJianmin Lu
May 6, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Di ZhaoShaowei Luo
Jul 15, 2017·Expert Review of Anticancer Therapy·Aayushi JainNilesh Kumar Sharma
Nov 25, 2017·Journal of Experimental & Clinical Cancer Research : CR·Xin YinZheng-Gang Ren
Dec 19, 2017·Japanese Journal of Clinical Oncology·Masafumi IkedaJunji Furuse
Nov 7, 2019·Journal of Clinical and Experimental Hepatology·Iliana Doycheva, Paul J Thuluvath

❮ Previous
Next ❯

Citations

Apr 27, 2021·Cancer Biology & Therapy·Fengchao Liu, Yanzhi Qian

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
Transfection
immunoprecipitation
PCR
electrophoresis
xenografts

Software Mentioned

SPSS

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aging Genetics (Keystone)

This feed focuses on aging epidemiology and genetic, epigenetic, and proteomic aspects underlying aging, as well as aging- associated biomarkers. Here the latest research in this domain.

Related Papers

Biochemical and Biophysical Research Communications
Atsushi SuetsuguHisataka Moriwaki
Journal of Biological Regulators and Homeostatic Agents
C Piechaczek
World Journal of Gastroenterology : WJG
Seiichi YoshikawaYasuni Nakanuma
© 2021 Meta ULC. All rights reserved